Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Alphamab Out-Licenses HER-2 Bispecific to CSPC in $150 Million Agreement

publication date: Aug 24, 2021

Suzhou Alphamab Oncology out-licensed China rights for its anti-HER2 bispecific antibody to CSPC Pharma in a deal worth up to $150 million, plus royalties. JMT-Bio, a CSPC subsidiary, will own KN026 rights for breast cancer and gastric or gastroesophageal junction cancers. It will be responsible for the cost of all clinical trials in China. Alphamab developed KN026 to bind two non-overlapping epitopes of HER2 simultaneously, leading to a dual HER2 signal blockade. More details....

Stock Symbols: (HK: 9966) (HK: 1093)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here